Should I buy or sell Benitec Biopharma stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Benitec Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BNTC shares. View BNTC analyst ratings or view top-rated stocks .

What is Benitec Biopharma's stock price target for 2024?

1 equities research analysts have issued 1-year price objectives for Benitec Biopharma's stock. Their BNTC share price targets range from $16.00 to $16.00. On average, they expect the company's stock price to reach $16.00 in the next year. This suggests a possible upside of 68.8% from the stock's current price. View analysts price targets for BNTC or view top-rated stocks among Wall Street analysts .

How have BNTC shares performed in 2024?

Benitec Biopharma's stock was trading at $3.23 at the beginning of the year. Since then, BNTC shares have increased by 193.5% and is now trading at $9.48. View the best growth stocks for 2024 here .

When is Benitec Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, September 19th 2024. View our BNTC earnings forecast .

When did Benitec Biopharma's stock split?

Shares of Benitec Biopharma reverse split on the morning of Wednesday, July 26th 2023. The 1-17 reverse split was announced on Wednesday, July 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of Benitec Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Benitec Biopharma investors own include Amarin (AMRN) , Pfizer (PFE) , Amicus Therapeutics (FOLD) , Sorrento Therapeutics (SRNE) , Arbutus Biopharma (ABUS) , Aldeyra Therapeutics (ALDX) , AVEO Pharmaceuticals (AVEO) , Anavex Life Sciences (AVXL) , BioLineRx (BLRX) and CRISPR Therapeutics (CRSP) .

When did Benitec Biopharma IPO?

Benitec Biopharma (BNTC) raised $0 in an initial public offering (IPO) on Thursday, August 6th 2015. The company issued 0 shares at a price of $0.00 per share. BMO Capital Markets and Maxim Group LLC acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

Who are Benitec Biopharma's major shareholders?

Benitec Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (9.44%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends .

How do I buy shares of Benitec Biopharma?

Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BNTC

Benitec Biopharma (BNTC) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Free BNTC Stock Alerts

$9.48

-0.01 (-0.11%)

(As of 09:33 AM ET)

Compare

Today's Range: $9.48
▼
$9.76
50-Day Range: $4.78
▼
$9.49
52-Week Range: $1.86
▼
$10.29

Volume: 7,470 shs
Average Volume: 61,913 shs
Market Capitalization: $88.83 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.00

Benitec Biopharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 68.8% Upside
$16.00 Price Target
Short Interest: Bearish
6.27% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.72
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.41 out of 5 stars

Medical Sector

731st out of 914 stocks

Pharmaceutical Preparations Industry

340th out of 427 stocks

3.5

Analyst's Opinion

Consensus Rating
Benitec Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Benitec Biopharma has only been the subject of 1 research reports in the past 90 days.
Read more about Benitec Biopharma's stock forecast and price target.

2.0

Short Interest

Percentage of Shares Shorted
6.27% of the float of Benitec Biopharma has been sold short.
Short Interest Ratio / Days to Cover
Benitec Biopharma has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Benitec Biopharma has recently increased by 707.38%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Benitec Biopharma does not currently pay a dividend.
Dividend Growth
Benitec Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BNTC.

2.6

News and Social Media Coverage

News Sentiment
Benitec Biopharma has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Benitec Biopharma this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for BNTC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Benitec Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Benitec Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.30% of the stock of Benitec Biopharma is held by insiders.
Percentage Held by Institutions
52.19% of the stock of Benitec Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Read more about Benitec Biopharma's insider trading history.

0.0

Earnings and Valuation

Price to Book Value per Share Ratio
Benitec Biopharma has a P/B Ratio of 79.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Read more about Benitec Biopharma's valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Benitec Biopharma Stock (NASDAQ:BNTC)

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

BNTC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BNTC Stock News Headlines

May 13, 2024 | finance.yahoo.com

Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update

May 13, 2024 | investorplace.com

BNTC Stock Earnings: Benitec Biopharma Misses EPS for Q3 2024

May 1, 2024 | finance.yahoo.com

Benitec Biopharma to Participate in the Citizens JMP Life Science Conference

April 18, 2024 | msn.com

Why Is Gene Therapy Developer Benitec Biopharma Stock Trading Higher On Thursday?

April 18, 2024 | finanznachrichten.de

Benitec Biopharma Inc.: Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study

April 18, 2024 | msn.com

Benitec Biopharma jumps 33% on $40M private financing

April 18, 2024 | markets.businessinsider.com

Why Benitec Biopharma Is Rising In Pre-market?

April 18, 2024 | globenewswire.com

Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study

April 18, 2024 | globenewswire.com

Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million

April 9, 2024 | finance.yahoo.com

Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024

March 24, 2024 | insidermonkey.com

11 Best ASX Stocks To Buy Now

February 25, 2024 | msn.com

Benitec Biopharma (BNTC) Price Target Increased by 66.67% to 10.20

February 13, 2024 | finance.yahoo.com

Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update

November 30, 2023 | finance.yahoo.com

Here's Why Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Compensation Is The Least Of Shareholders Concerns

November 30, 2023 | finance.yahoo.com

Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

November 19, 2023 | morningstar.com

Benitec Biopharma Inc BNTC

November 17, 2023 | finance.yahoo.com

Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference

November 15, 2023 | finanznachrichten.de

Benitec Biopharma Inc.: Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update

November 14, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Benitec Biopharma (BNTC), Rezolute (RZLT)

November 13, 2023 | finance.yahoo.com

Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update

September 27, 2023 | msn.com

JMP Securities Maintains Benitec Biopharma (BNTC) Market Outperform Recommendation

September 26, 2023 | markets.businessinsider.com

JMP Securities Sticks to Its Buy Rating for Benitec Biopharma (BNTC)

September 21, 2023 | finance.yahoo.com

Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update

August 21, 2023 | finance.yahoo.com

Citadel Advisors LLC Acquires New Stake in Benitec Biopharma Inc

August 11, 2023 | finance.yahoo.com

Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering

See More Headlines

Company Calendar

Today: 5/20/2024
Fiscal Year End: 6/30/2024
Next Earnings (Estimated): 9/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:BNTC
CUSIP: N/A
CIK: 1808898
Web: www.benitec.com
Phone: 510-780-0819
Fax: 61 (0)3 9966-9923
Employees: 16
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $16.00
High Stock Price Target: $16.00
Low Stock Price Target: $16.00
Potential Upside/Downside: +68.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,560,000.00
Net Margins: N/A
Pretax Margin: -309,885.78%
Return on Equity: -175.36%
Return on Assets: -127.85%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 4.18
Quick Ratio: 3.62

Sales & Book Value

Annual Sales: $7,000.00
Price / Sales: 12,700.33
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.23 per share
Price / Book: 7.72

Miscellaneous

Outstanding Shares: 9,368,000
Free Float: 8,965,000
Market Cap: $88.90 million
Optionable: No Data
Beta: 0.80

Key Executives

Dr. Jerel A. Banks M.D. (Age 49)
Ph.D., Executive Chairman & CEO
Comp: $848.07k
Ms. Megan Joan Boston BComm (Age 52)
CA, Dip., GAICD, Executive Director
Comp: $439.17k
Dr. Michael Graham
Head of Discovery & Founding Scientist
Dr. Claudia Kloth
Senior Vice President of Manufacturing

Key Competitors

View All Competitors

Institutional Ownership

Janus Henderson Group PLC
Bought 64,092 shares on 5/16/2024
Ownership: 9.440%

View All Institutional Transactions

BNTC Stock Analysis - Frequently Asked Questions

Should I buy or sell Benitec Biopharma stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Benitec Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BNTC shares.
View BNTC analyst ratings or view top-rated stocks.
What is Benitec Biopharma's stock price target for 2024?: 1 equities research analysts have issued 1-year price objectives for Benitec Biopharma's stock. Their BNTC share price targets range from $16.00 to $16.00. On average, they expect the company's stock price to reach $16.00 in the next year. This suggests a possible upside of 68.8% from the stock's current price.
View analysts price targets for BNTC or view top-rated stocks among Wall Street analysts.
How have BNTC shares performed in 2024?: Benitec Biopharma's stock was trading at $3.23 at the beginning of the year. Since then, BNTC shares have increased by 193.5% and is now trading at $9.48.
View the best growth stocks for 2024 here.
When is Benitec Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, September 19th 2024.
View our BNTC earnings forecast.
When did Benitec Biopharma's stock split?: Shares of Benitec Biopharma reverse split on the morning of Wednesday, July 26th 2023. The 1-17 reverse split was announced on Wednesday, July 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of Benitec Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), Amicus Therapeutics (FOLD), Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL), BioLineRx (BLRX) and CRISPR Therapeutics (CRSP).
When did Benitec Biopharma IPO?: Benitec Biopharma (BNTC) raised $0 in an initial public offering (IPO) on Thursday, August 6th 2015. The company issued 0 shares at a price of $0.00 per share. BMO Capital Markets and Maxim Group LLC acted as the underwriters for the IPO and Roth Capital Partners was co-manager.
Who are Benitec Biopharma's major shareholders?: Benitec Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (9.44%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.
How do I buy shares of Benitec Biopharma?: Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BNTC) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Benitec Biopharma (BNTC) Stock Price, News & Analysis

Benitec Biopharma MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows